Examkin

Soru

Zorluk: ZorSleep-Wake Disorders

A 31-year-old man comes to the clinic accompanied by his husband due to daytime sleep attacks and episodes of sudden muscle weakness. Over the last 5 months, he has been sleeping 9 to 10 hours per night but still struggles to stay awake during his work as a financial analyst. He reports that when he laughs heartily at a joke, his knees buckle and he occasionally drops his briefcase, though he remains fully conscious. Last month, while falling asleep, he saw a terrifying shadowy figure in his room and was unable to move his limbs for approximately a minute. His medical history is notable for a manic episode at age 22, leading to a diagnosis of bipolar I disorder. He was previously taking valproate but discontinued it a year ago due to weight gain. He is currently taking only tranylcypromine, which was prescribed 2 months ago for an acute depressive episode. Vital signs are within normal limits. Physical examination is unremarkable. Laboratory studies show a thyroid-stimulating hormone (TSH) level of 7.2 µU/mL (normal: 0.5-5.0 µU/mL) and a free thyroxine (T4) level of 1.2 ng/dL (normal: 0.9-1.7 ng/dL).

Which of the following is the most appropriate pharmacotherapy for this patient's sleep-related symptoms?

  1. A
    Fluoxetine
  2. B
    Levothyroxine
  3. C
    Risperidone
  4. Sodium oxybateCevap
  5. E
    Venlafaxine

Cevap

Sodium oxybate
Sodium oxybate is an FDA-approved, highly effective treatment for both the excessive daytime sleepiness and cataplexy associated with Narcolepsy Type 1. It acts as a central nervous system depressant (via GABA-B and GHB receptors) to consolidate fragmented nighttime sleep. Crucially, in this complex patient, sodium oxybate does not carry serotonergic activity, meaning it can be safely co-administered with his current monoamine oxidase inhibitor (tranylcypromine) without causing serotonin syndrome. Furthermore, unlike activating antidepressants, it does not carry a high risk of precipitating a manic episode in a patient with bipolar I disorder who is currently off mood stabilizers.

Adım Adım Çözüm

1
Identify the primary diagnosis based on the clinical presentation.
The patient's excessive daytime sleepiness, cataplexy (muscle weakness triggered by laughter), hypnagogic hallucinations, and sleep paralysis are diagnostic of Narcolepsy Type 1.
Recognizing the full tetrad of narcolepsy symptoms differentiates it from other causes of fatigue, such as hypothyroidism or depression.
2
Evaluate the patient's current medication regimen and medical history for potential contraindications.
The patient has Bipolar I disorder not covered by a mood stabilizer, and is currently taking tranylcypromine, a monoamine oxidase inhibitor (MAOI).
Standard off-label cataplexy treatments (SSRIs/SNRIs) pose extreme risks in this specific patient, including manic switch and serotonin syndrome.
3
Select the appropriate therapy that safely addresses the core symptoms.
Sodium oxybate is chosen as the most appropriate pharmacotherapy.
It treats both excessive daytime sleepiness and cataplexy effectively without interacting with the MAOI or precipitating mania.

Anahtar Kavram

Management of Narcolepsy Type 1 in patients with psychiatric comorbidities and complex medication regimens.
Bu soruyu puanla

Konular

Sleep-Wake Disorders

Bu konudan daha fazla soru